182 related articles for article (PubMed ID: 20461090)
1. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha.
Yang S; de Souza P; Alemao E; Purvis J
Br J Cancer; 2010 May; 102(10):1456-60. PubMed ID: 20461090
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
3. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.
Zbrozek AS; Hudes G; Levy D; Strahs A; Berkenblit A; DeMarinis R; Parasuraman S
Pharmacoeconomics; 2010; 28(7):577-84. PubMed ID: 20550223
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):61-8. PubMed ID: 19804430
[TBL] [Abstract][Full Text] [Related]
5. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Maroto JP; Hudes G; Dutcher JP; Logan TF; White CS; Krygowski M; Cincotta M; Shapiro M; Duran I; Berkenblit A
J Clin Oncol; 2011 May; 29(13):1750-6. PubMed ID: 21444868
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus: in advanced renal cell carcinoma.
Simpson D; Curran MP
Drugs; 2008; 68(5):631-8. PubMed ID: 18370442
[TBL] [Abstract][Full Text] [Related]
8. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Figlin RA; de Souza P; McDermott D; Dutcher JP; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Boni J; Hudes G
Cancer; 2009 Aug; 115(16):3651-60. PubMed ID: 19526589
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
Bellmunt J; Szczylik C; Feingold J; Strahs A; Berkenblit A
Ann Oncol; 2008 Aug; 19(8):1387-1392. PubMed ID: 18385198
[TBL] [Abstract][Full Text] [Related]
10. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
Kwitkowski VE; Prowell TM; Ibrahim A; Farrell AT; Justice R; Mitchell SS; Sridhara R; Pazdur R
Oncologist; 2010; 15(4):428-35. PubMed ID: 20332142
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
12. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
[TBL] [Abstract][Full Text] [Related]
13. Temsirolimus: new drug. Metastatic kidney cancer: more assessment needed.
Prescrire Int; 2008 Dec; 17(98):223-5. PubMed ID: 19415885
[TBL] [Abstract][Full Text] [Related]
14. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
Dutcher JP; de Souza P; McDermott D; Figlin RA; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Hudes G
Med Oncol; 2009; 26(2):202-9. PubMed ID: 19229667
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
Cella D; Michaelson MD; Bushmakin AG; Cappelleri JC; Charbonneau C; Kim ST; Li JZ; Motzer RJ
Br J Cancer; 2010 Feb; 102(4):658-64. PubMed ID: 20104222
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
Castellano D; del Muro XG; Pérez-Gracia JL; González-Larriba JL; Abrio MV; Ruiz MA; Pardo A; Guzmán C; Cerezo SD; Grande E
Ann Oncol; 2009 Nov; 20(11):1803-12. PubMed ID: 19549706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
